MicroPort^® NeuroTech NUMEN Coil Embolization System Approved for Market in Korea

Seoul, Republic of Korea, 10 September 2021 — The NUMEN® Coil Embolization System (NUMEN®) and NUMEN FR® Detachment System (NUMEN FR®), developed by MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech), recently received approval for marketing from the Korea Ministry of Food and Drug Safety (MFDS).

With its stable embolization and dense packing, NUMEN® is primarily used in endovascular coiling procedures for the treatment of intracranial aneurysms. It is available in different lengths to provide doctors a full range of embolization options and to help ensure the safety of patients. The NUMENFR® is used in conjunction with NUMEN® to assist in coil detachment.

NUMEN® and NUMEN FR® have been previously approved for marketing in China and the EU, and in addition, were recently used for the first time in Chile, marking the first implantation in an overseas market.

As one of the most important markets in the Asia-Pacific region, South Korea has an enormous market potential for medical devices. The approval of NUMEN® and NUMEN FR® in Korea will help MicroPort® NeuroTech further penetrate the Korean market.

About intracranial aneurysm

An intracranial aneurysm is an abnormal dilation that occurs on the walls of intracranial arteries. Among all cerebrovascular accidents, the prevalence of intracranial aneurysms is the third highest, after cerebral thrombosis and hypertensive cerebral hemorrhage[1]. In Asian populations, the prevalence of intracranial aneurysms ranges from 2.5 to 3.0 percent. The possibility of aneurysm rupture increases over time, and intracranial aneurysms are known as “a ticking time bomb in the head” due to their high mortality and morbidity rate upon rupture.